New drug aims to unmask melanoma to the immune system

NCT ID NCT03161431

Ongoing Disease control Sponsor: Syntrix Biosystems, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tests a new oral drug, SX-682, combined with the immunotherapy pembrolizumab in people with advanced melanoma. The goal is to see if SX-682 can stop cancer from hiding from the immune system, making the immunotherapy work better. About 77 participants will receive SX-682 alone first, then both drugs together for up to two years.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SX-682 (an oral drug that blocks cancer from hiding from the immune system) and pembrolizumab (an immunotherapy that helps immune cells attack cancer)
What this could lead to: If it works, this could point toward a new combination treatment that makes immunotherapy more effective for people with advanced melanoma.
What could go wrong: This is an early Phase 1 trial with only 77 participants, so safety and effectiveness are not yet proven. The drug may cause side effects or fail to improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MELANOMA STAGE III are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

melanoma metastatic melanoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MELANOMA STAGE III MELANOMA STAGE IV

Contacts and locations

Locations

Dana-Farber Cancer Institute

Boston, Massachusetts, 02215, United States
MD Anderson

Houston, Texas, 77030, United States
Massachusetts General Hospital Cancer Center

Boston, Massachusetts, 02114, United States
Mayo Clinic

Rochester, Minnesota, 55905, United States
University of Miami

Miami, Florida, 33136, United States
Wilmot Cancer Institute - University of Rochester

Rochester, New York, 14642, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.